LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Metagenomic Sequencing Can Diagnose Cases of Meningitis

By LabMedica International staff writers
Posted on 01 May 2018
Print article
Image: A photomicrograph of a brain tissue specimen revealed the presence of hooklets in a case of cysticercosis, an infection due to the ingestion of eggs of a pork tapeworm, Taenia solium (Photo courtesy of the University of Pennsylvania Medical Center).
Image: A photomicrograph of a brain tissue specimen revealed the presence of hooklets in a case of cysticercosis, an infection due to the ingestion of eggs of a pork tapeworm, Taenia solium (Photo courtesy of the University of Pennsylvania Medical Center).
Subacute and chronic meningitis are diagnostically challenging given the wide range of potential infectious, autoimmune, neoplastic, paraneoplastic, parameningeal, and toxic causes. Securing a final diagnosis can require weeks or months of testing or remain unsolved, necessitating empirical treatment approaches that may be ineffective or even harmful.

Unlike traditional testing for specific microbes or categories of infection, metagenomic next-generation sequencing (mNGS) of cerebrospinal fluid (CSF) or brain tissue screens for nearly all potential central nervous system (CNS) infections and can identify novel or unexpected pathogens. However, mNGS data require careful analysis to determine which, if any, of the identified microbes represent a true pathogen rather than environmental contamination.

A large team of scientists led by those at University of California, San Francisco (San Francisco, CA, USA) enrolled seven patients who were recruited between September 2013 and March 2017 as part of a larger study applying mNGS to biological samples from patients with suspected neuroinflammatory disease. The seven participants enrolled in the present study had subacute or chronic leptomeningitis with or without encephalitis.

The team performed metagenomic next-generation sequencing on total RNA extracted from surplus CSF (250-500 μL), and one participant also had mNGS performed on total RNA extracted from snap frozen surplus tissue (<50 mg) obtained from a lumbar meningeal biopsy. Paired-end sequences of 125 to 150 base pairs were analyzed using a previously described rapid computational pathogen detection pipeline consisting of open-source components.

To distinguish putative pathogens from contaminating microbial sequences derived from skin, collection tubes, laboratory reagents, or the environment, a composite background model of metagenomic data was used. This model incorporated 24 water control samples and 94 CSF samples from patients with noninfectious diagnoses, including 21 patients with chronic meningitis with or without encephalitis.

The seven participants ranged in age from 10 to 55 years, and three (43%) were female. A parasitic worm, Taenia solium in two participants, a virus (HIV-1), and four fungi: Cryptococcus neoformans, Aspergillus oryzae, Histoplasma capsulatum, and Candida dubliniensis were identified among the seven participants by using mNGS.

The authors concluded that diverse microbial pathogens were identified by mNGS in the CSF of patients with diagnostically challenging subacute or chronic meningitis, including a case of subarachnoid neurocysticercosis that defied diagnosis for one year, the first reported case of CNS vasculitis caused by Aspergillus oryzae, and the fourth reported case of C. dubliniensis meningitis. The study was published on April 16, 2018, in the journal JAMA Neurology.

Related Links:
University of California, San Francisco

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
H.pylori Test
Humasis H.pylori Card
New
Auto Clinical Chemistry Analyzer
cobas c 703

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.